Management of fever in neutropenic patients with different risks of complications

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Jean Klastersky

Abstract

Risk stratification of febrile neutropenic patients can have important implications in terms of management. The first prospectively validated risk scoring system was developed in 1992. A subsequent scoring system was developed in 2000, in which a score of < or =21 predicts a <5% risk for severe complications. Oral combination therapy in an ambulatory or home care setting is acceptable for low-risk patients. Hospital admission is mandatory for high-risk patients. Intravenous monotherapy can be given if neutropenia is anticipated to be of short duration; it is also acceptable if neutropenia is expected to be more prolonged but the patients is stable and do not have an infectious focus. All other patients should receive combination therapy with an aminoglycoside, if infection with a gram-negative pathogen is suspected, or a glycopeptide, if a gram-positive organism is suspected. However, antimicrobial therapy with coverage against gram-negative organisms should always be provided because of the significant mortality associated with these infections.

References

Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A TalcottL Goldman
Dec 31, 1987·The New England Journal of Medicine·UNKNOWN EORTC International Antimicrobial Therapy Cooperative GroupS H Zinner
Jan 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C CordonnierJ J Gres
Aug 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L S EltingG P Bodey
Feb 26, 2000·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·H AriffinL H Peng
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J KlasterskyJ Talcott
Apr 18, 2001·Chemotherapy·B M JándulaJ Sierra
Jan 25, 2002·The New England Journal of Medicine·Lawrence Corey, Michael Boeckh
Dec 1, 1962·Archives of Internal Medicine·B W FRANK, F KERN

❮ Previous
Next ❯

Citations

Dec 8, 2004·Der Internist·X SchielH Ostermann
Dec 7, 2007·Intensive Care Medicine·R Phillip DellingerJean-Louis Vincent
Jan 31, 2013·Intensive Care Medicine·R P DellingerUNKNOWN Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup
Oct 19, 2007·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Alison FreifeldJunfeng Sun
Jan 21, 2006·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·E VelascoV M S C Gonçalves
Oct 7, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M ElligsenA Simor
Jan 29, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·E MontassierM F de La Cochetière
Jun 29, 2013·Clinical Pharmacokinetics·Tiphaine Goulenok, Bruno Fantin
Jul 14, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Juan J Picazo
Jul 14, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kenneth V I Rolston
Dec 6, 2011·Journal of Paediatrics and Child Health·Aditi Vedi, Richard Cohn
May 24, 2011·Annals of Clinical Microbiology and Antimicrobials·Manju PanghalJaya P Yadav
Nov 21, 2012·Infectious Agents and Cancer·Kenneth AlibekBolat Sultankulov
Jan 6, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alison G Freifeld Infectious Diseases Society of Americaa
Jan 25, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alison G Freifeld Infectious Diseases Society of America
Mar 8, 2013·Hospital Practice·Aarti S Bhardwaj, Shyamala C Navada
Jul 3, 2015·Molecular and Clinical Oncology·Javier DE Castro CarpeñoFrancisco José Rebollo Laserna
Aug 6, 2013·Mayo Clinic Proceedings·Livia T HegerovaShaji K Kumar
Jan 21, 2016·Virulence·Carlota GudiolJordi Carratalà
Oct 30, 2010·The American Journal of Emergency Medicine·Charles LimBrian H Rowe
Jan 10, 2006·British Journal of Haematology·Rodrigo Martino, Claudio Viscoli
Jan 29, 2011·Internal Medicine Journal·L J WorthUNKNOWN Australian Consensus Guidelines 2011 Steering Committee
Jan 29, 2011·Internal Medicine Journal·C S TamUNKNOWN Australian Consensus Guidelines 2011 Steering Committee
Apr 16, 2011·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Inge Kristine LarsenHenrik C Schønheyder
Mar 24, 2016·Virulence·Giulia Gustinetti, Malgorzata Mikulska
Mar 31, 2015·Critical Reviews in Oncology/hematology·Aurora MirabileR Phillip Dellinger
Mar 6, 2007·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Zeina A KanafaniSouha S Kanj
Feb 2, 2015·Revista brasileira de hematologia e hemoterapia·Matilde Boada BurutaranLilian Diaz
Dec 6, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Yosuke SuzukiJun-ichi Kadota
Jan 13, 2017·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Allison R ButtsVal R Adams
Jan 16, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher R FlowersScott D Ramsey
Jan 9, 2015·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·A D NguyenS Gilmore
Feb 1, 2013·Therapeutic Advances in Infectious Disease·Sehnaz Alp, Murat Akova
Apr 3, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ron RamRonen Ben-Ami

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

© 2022 Meta ULC. All rights reserved